3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction - Related Studies

3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction

This study is ongoing, but not recruiting participants.

Study NCT00077545. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Esophageal Cancer

2	Additional conditions recognized in this trial
		Adenocarcinoma
		Esophageal Diseases
		Esophageal Neoplasms

3	More general conditions related to this trial
		Carcinoma
		Digestive System Diseases
		Digestive System Neoplasms
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Head and Neck Neoplasms
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial

4	Interventions listed in this trial
		cisplatin
		triapine

5	More general drug interventions related to this trial
		Antineoplastic Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		University of Chicago
		National Cancer Institute (NCI)